BioSig Technologies Files S-1 for Security Offering

TL;DR

BioSig just filed an S-1, looks like they're raising cash.

AI Summary

BioSig Technologies, Inc. filed an S-1 form with the SEC on June 27, 2024, to register securities. The company, incorporated in Delaware and headquartered in Westport, CT, operates in the electromedical and electrotherapeutic apparatus industry. The filing indicates a proposed sale of securities, with Anthony Amato serving as CEO and agent for service.

Why It Matters

This S-1 filing signals BioSig Technologies' intent to raise capital through the sale of securities, which could impact its future operations and stock valuation.

Risk Assessment

Risk Level: medium — S-1 filings are typically associated with capital raises, which can introduce dilution and market uncertainty.

Key Numbers

• 3845 — SIC Code (Industry classification for Electromedical & Electrotherapeutic Apparatus)
• 26-4333375 — IRS Number (Company's Employer Identification Number)

Key Players & Entities

• BioSig Technologies, Inc. (company) — Registrant
• 20240627 (date) — Filing Date
• 333-280525 (dollar_amount) — SEC File Number
• 55 Greens Farms Road, Westport, CT 06880 (company) — Principal Executive Offices Address
• Anthony Amato (person) — Chief Executive Officer and Agent for Service
• Gregory Sichenzia (person) — Legal Counsel
• Avital Perlman (person) — Legal Counsel
• Sichenzia Ross Ference Carmel LLP (company) — Legal Counsel Firm

FAQ

Key Financial Figures

• $0.001 — 1 shares of our common stock, par value $0.001 per share, issuable upon the exercise o
• $3,058,317 — ants, for an aggregate of approximately $3,058,317. Our registration of the shares of co
• $0.368 — ed sales price for our common stock was $0.368 per share. Investment in our common s
• $1.00 — k did not meet the minimum bid price of $1.00 per share required for continued listin
• $5,000,000 m — se the Company does not comply with the $5,000,000 minimum stockholders’ equity initia
• $35 m — um Market Value of Listed Securities of $35 million, if none of the other standards s
• $2.5 million — he Nasdaq Capital Market, including the $2.5 million stockholders’ equity requirement
• $1.4605 — o;s common stock at a purchase price of $1.4605 per share, and warrants to purchase up
• $1.398 — of common stock at an exercise price of $1.398 per share, that will become exercisable
• $1,144,164 — exchange for aggregate consideration of $1,144,164, including $634,999 in cash and $509,16
• $634,999 — consideration of $1,144,164, including $634,999 in cash and $509,165 representing conve
• $509,165 — 144,164, including $634,999 in cash and $509,165 representing conversion of the principa
• $15,000 — des for compensation at a fixed rate of $15,000 per month and reimbursement by the Comp

Filing Documents

• forms-1.htm (S-1) — 342KB
• ex5-1.htm (EX-5.1) — 11KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 73KB
• forms-1_001.jpg (GRAPHIC) — 5KB
• forms-1_002.jpg (GRAPHIC) — 5KB
• ex5-1_001.jpg (GRAPHIC) — 6KB
• 0001493152-24-025420.txt ( ) — 453KB

RISK FACTORS

RISK FACTORS 5 SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS 5

USE OF PROCEEDS

USE OF PROCEEDS 6 SELLING STOCKHOLDERS 6

DESCRIPTION OF SECURITIES BEING REGISTERED

DESCRIPTION OF SECURITIES BEING REGISTERED 10 PLAN OF DISTRIBUTION 10 LEGAL MATTERS 12 EXPERTS 12 WHERE YOU CAN FIND MORE INFORMATION 13 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 13 i ABOUT THIS PROSPECTUS This prospectus is part of the registration statement that we filed with the SEC pursuant to which the selling stockholders named herein may, from time to time, offer and sell or otherwise dispose of the shares of our common stock covered by this prospectus. As permitted by the rules and regulations of the SEC, the registration statement filed by us includes additional information not contained in this prospectus. This prospectus and the documents incorporated by reference into this prospectus include important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or shares of common stock are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus, including the documents incorporated by reference therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you under “Where You Can Find More Information” and “Incorporation of Certain Information by Reference” in this prospectus. You should rely only on this prospectus and the information incorporated or deemed to be incorporated by reference in this prospectus. We have not, and the selling stockholders have not, authorized anyone to give any information or to make any representation

View Full Filing

View this S-1 filing on SEC EDGAR